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Summary. This review outlines the principal limitations 
of the mechanisms of active cell death (ACD, apoptosis) 
as the basis of tumorigenesis and the rationale of almost 
all therapies of malignancy. The concentration of cancer 
therapy in the directon of ACD induction is presented as 
both the result of progressive understanding of the 
mechanisms of apoptosis and that of the favourable 
tumor environment for ACD signal transmission. The 
latter property induces the by-stander killing of cancer 
cells, a fundamental mechanism because efficiency of all 
known methods of cancer treatment is far below 100%. 
Finally, recent results and hypotheses regarding cancer 
gene therapy based on final inductors of apoptosis and 
endogeneous ACD inhibitors in tumors are evaluated. 
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Introduction: Cell loss factor in tumors 
In current years, the simplistic view considering 
cancer the result of enhanced cell proliferation is being 
quickly replaced by the broader image of malignancy as 
consisting in an anomalous accumulation of cells, 
implying that the comparative rates of cell proliferation 
and cell death determine how fast a tumor grows. 
Actually, there are cancer cells which divide more 
slowly than their benign origin cells, being malignant 
only due to delayed cell death (Green et al., 1994; Kerr 
et al., , 1994). 
However, the balance between cell gain through 
mitosis and cell loss in neoplasia is tight, because cell 
loss is large. Cell production can be obtained either from 
the labeling index (i.e. the proportion of cells 
incorporating labeled thymidine after a labeling pulse) or 
from the mitotic index (i.e. the percentage of mitotic 
cells). These evaluations allow the calculation of the 
potential doubling time (Tp, i.e. the time in which the 
cell number would have doubled had there been no cell 
loss). The actual doubling time (Ta) is given by direct 
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measurements of tumors. These two parameters permit 
the calculation of the cell loss factor (CLF = 1 - TpRa). 
With no cell loss, CLF is zero; it tends to unity if loss is 
so extensive that Ta becomes very large. One cardinal 
characteristic of virtually all tumors which have been 
submitted to this type of measurements is that cell loss 
factors are huge. Even in transplantable animal tumors 
selected for rapid growth CLF exceeds 0.6. In aggressive 
human cancers values are still higher, such as 0.73 in 
melanoma, 0.96 in colorectal carcinoma and range from 
0.71 to 0.99 in pulmonary tumors of different 
histological types. Moreover, the cell loss factor 
augments during tumor enlargement. Three main types 
of cell loss occur in tumors: exfoliation, metastasis and 
cell death, with the latter factor accounting for the 
majority of cell elimination (Kerr and Lamb, 1984; 
Steel, 1967, 1968; Wyllie, 1985; Granville et al., 1998). 
Malignant tumors frequently contain necrosis. 
Equivalent to passive cell death, necrosis is the result of 
hypoxia since it occurs at a distance from blood vessels 
which is quite constant for individual tumors and its 
extension is influenced by the level of oxygenation of 
the blood (Schatten, 1962). Though conspicuous 
histologically, necrosis does not satisfactorily account 
for most of the cell losses predicted on the basis of CLF 
since important loss factors can occur in turnors with 
high mitotic indices and no necrosis. It is therefore likely 
that apoptosis is responsible for an important part of cell 
death in cancer. The term "apoptosis" was coined to 
describe genetically driven, active, cell death (ACD). 
And indeed, apoptosis exists in all malignant lesions. 
The factors responsible for the universal spontaneous 
occurrence of ACD in tumors are not unequivocally 
established. They presumably belong to two classes: 1) 
cell population regulatory mechanisms originating in the 
host organism, the so-called "social controls on cell 
death"; and 2) apoptosis initiated by processes intrinsic 
to malignant cells (Schatten, 1962; Kerr and Searle, 
1972; Kerr et al., 1972, 1994; Wyllie et al., 1980; Wyllie, 
1985; Sarraf and Bowen, 1988; Raff, 1992; Staunton and 
Gaffney, 1995; Granville et al., 1998; Soini et al., 1998). 
Due to the relative rapidity of the phenomenon (10 
minutes to 40 hours for chromatin condensation and cell 
fragmentation, 3 hours for apoptotic-body phagocytosis 
and digestion), strong ACD-induced tissular decrease is 
















